Harrow Health Inc
NASDAQ:HROW
Harrow Health Inc
NASDAQ:HROW
Price:
35.2
USD
3.53%
Market Closed
Market Cap:
$1.3B
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Harrow Health Inc
NASDAQ:HROW
|
US |
Relative Value
The Relative Value of one
HROW
stock under the Base Case scenario is
50.83
USD.
Compared to the current market price of 35.2 USD,
Harrow Health Inc
is
Undervalued by 31%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
HROW
Relative Value
Base Case
50.83
USD
Undervaluation 31%
Multiples Across Competitors
HROW Competitors Multiples
Harrow Health Inc Competitors
Harrow Health Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
Harrow Health Inc
NASDAQ:HROW
|
1.3B USD | 4.8 | -255 | 30 | 48.5 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
853.2B USD | 13.1 | 41.3 | 27.9 | 29.8 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
566.5B USD | 6 | 21.1 | 14.7 | 18.1 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
243.4B CHF | 4 | 18.9 | 11.2 | 12.6 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
214.2B GBP | 4.9 | 28.3 | 15.7 | 22.2 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
288B USD | 4.4 | 15.8 | 9.8 | 11.9 | |
| CH |
|
Novartis AG
SIX:NOVN
|
225.4B CHF | 5.2 | 21.1 | 13.1 | 16.8 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
237.1B USD | 102.3 | -81.1 | 375.3 | 941.3 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 3.4 | 10.3 | 7.7 | 9 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
153.3B USD | 2.4 | 19.7 | 7.6 | 10.1 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
115.5B USD | 2.4 | 16.4 | 7 | 8.6 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
